血清miR-6861-5p联合CA153对乳腺癌的诊断价值
|
摘要
目的研究血清微小RNA-6861-5p(miR-6861-5p)联合糖类抗原153(CA153)对乳腺癌的诊断价值。方法选择2015年4月～2018年4月辽宁省鞍山市肿瘤医院(以下简称"我院")收治的乳腺癌患者83例为研究对象,作为乳腺癌组。另取同期于我院接受诊治的乳腺良性疾病患者80例作为乳腺良性疾病组,再取同期在我院进行体检的健康人者80名作为对照组。分别采用实时荧光定量聚合酶链反应检测各组人员血清miR-6861-5p表达情况,采用化学发光法检测血清CA153水平。比较三组血清miR-6861-5p与CA153水平,并分析上述两项指标与乳腺癌患者临床病理特征的关系。采用受试者工作特征(ROC)曲线分析血清miR-6861-5p与CA153水平联合检测对乳腺癌的诊断效能。结果乳腺癌组患者血清miR-6861-5p与CA153水平分别高于乳腺良性疾病组与对照组,差异有统计学意义(均P <0.05)。Ⅰ～Ⅱ期与无淋巴结转移的乳腺癌患者血清miR-6861-5p水平分别低于Ⅲ～Ⅳ期与有淋巴结转移患者,差异有统计学意义(均P <0.05)。Ⅰ～Ⅱ期与无淋巴结转移的乳腺癌患者血清CA153水平分别低于Ⅲ～Ⅳ期与有淋巴结转移患者,差异有统计学意义(均P <0.05)。miR-6861-5p联合CA153检测诊断乳腺癌的敏感度、特异度均高于miR-6861-5p与CA153水平单独检测(均P <0.05)。结论血清miR-6861-5p联合CA153检测应用于乳腺癌患者中具有较高的诊断效能,可作为临床上诊断乳腺癌的一种有效手段。
Objective To study the diagnostic value of serum micro RNA-6861-5 p(miR-6861-5 p) combined with carbohydrate antigen 153(CA153) in breast cancer. Methods A total of 83 cases of breast cancer patients admitted to Anshan Tumor Hospital(hereinafter referred to as "our hospital") from April 2015 to April 2018 were selected, which were recorded as the breast cancer group. In addition, 80 patients with benign breast diseases who received diagnosis and treatment in our hospital during the same period were selected as the benign breast disease group, and 80 healthy people who underwent physical examination in our hospital during the same period were selected as the control group.Real-time fluorescence quantitative polymerase chain reaction was used to detect the expression of serum miR-6861-5 p in each group, and the serum CA153 level was detected by chemiluminescence. The levels of serum miR-6861-5 p and CA153 in the three groups were compared, and the relationship between the above two indicators and the clinicopathological characteristics of breast cancer patients was analyzed. The diagnostic efficacy of serum miR-6861-5 p combined with CA153 levels in breast cancer was analyzed using the receiver operating characteristic(ROC) curve. Results The levels of serum miR-6861-5 p and CA153 in the breast cancer group were higher than those in the benign breast disease group and the control group, with statistically significant differences(all P < 0.05). Ⅰ-Ⅱ period with no lymph node metastasis of breast cancer patients serum miR-6861-5 P levels were lower than Ⅲ-Ⅳ period and the patients with lymph node metastasis, the differences were statistically significant(all P < 0.05). Ⅰ-Ⅱ period with no lymph node metastasis of breast cancer patients serum CA153 levels were lower than Ⅲ-Ⅳ period and the patients with lymph node metastasis, the differences were statistically significant(all P < 0.05). The sensitivity and specificity under the curve of miR-6861-5 p combined with CA153 in diagnosis of breast cancer were all higher than those of miR-6861-5 p and CA153 alone(all P < 0.05). Conclusion The application of serum miR-6861-5 p combined with CA153 detection in breast cancer patients has high diagnostic efficacy, and can be used as an effective means for clinical diagnosis of breast cancer.
Objective To study the diagnostic value of serum micro RNA-6861-5 p(miR-6861-5 p) combined with carbohydrate antigen 153(CA153) in breast cancer. Methods A total of 83 cases of breast cancer patients admitted to Anshan Tumor Hospital(hereinafter referred to as "our hospital") from April 2015 to April 2018 were selected, which were recorded as the breast cancer group. In addition, 80 patients with benign breast diseases who received diagnosis and treatment in our hospital during the same period were selected as the benign breast disease group, and 80 healthy people who underwent physical examination in our hospital during the same period were selected as the control group.Real-time fluorescence quantitative polymerase chain reaction was used to detect the expression of serum miR-6861-5 p in each group, and the serum CA153 level was detected by chemiluminescence. The levels of serum miR-6861-5 p and CA153 in the three groups were compared, and the relationship between the above two indicators and the clinicopathological characteristics of breast cancer patients was analyzed. The diagnostic efficacy of serum miR-6861-5 p combined with CA153 levels in breast cancer was analyzed using the receiver operating characteristic(ROC) curve. Results The levels of serum miR-6861-5 p and CA153 in the breast cancer group were higher than those in the benign breast disease group and the control group, with statistically significant differences(all P < 0.05). Ⅰ-Ⅱ period with no lymph node metastasis of breast cancer patients serum miR-6861-5 P levels were lower than Ⅲ-Ⅳ period and the patients with lymph node metastasis, the differences were statistically significant(all P < 0.05). Ⅰ-Ⅱ period with no lymph node metastasis of breast cancer patients serum CA153 levels were lower than Ⅲ-Ⅳ period and the patients with lymph node metastasis, the differences were statistically significant(all P < 0.05). The sensitivity and specificity under the curve of miR-6861-5 p combined with CA153 in diagnosis of breast cancer were all higher than those of miR-6861-5 p and CA153 alone(all P < 0.05). Conclusion The application of serum miR-6861-5 p combined with CA153 detection in breast cancer patients has high diagnostic efficacy, and can be used as an effective means for clinical diagnosis of breast cancer.
引文
[1]范青,郑维.WNT/β-catenin信号通路与miRNA在乳腺癌发生发展中的作用进展[J].中国医师杂志,2018,20(2):311-314.
[2]张同成,陆振一,薛世航,等.CA153、CA125、CA199、AFP和CEA在海岛地区农村乳腺癌中的诊断意义[J].现代实用医学,2017,29(11):1492-1494.
[3]戴建刚,吴永丰,李美,等.乳腺癌患者肿瘤标志物、免疫球蛋白、TNF-α和hs-CRP水平的变化及其临床意义[J].海南医学院学报,2017,23(20):2822-2825.
[4]梅虹,李常恩,杨梁,等.长链非编码RNA LINC01001在乳腺癌中的表达及其对MCF-7细胞增殖的影响[J].中国肿瘤生物治疗杂志,2018,25(2):158-162.
[5]杨文蔚,王志恒,岳朝艳,等.乳腺癌患者血清CA153、CEA、铁蛋白和降钙素水平的变化及临床意义[J].检验医学,2017,32(4):308-310.
[6]吴立春,谷仕艳,代黄梅,等.长链非编码RNA-ROR在乳腺癌患者血清、癌组织中的表达变化及其临床意义[J].山东医药,2017,57(32):78-80.
[7]闫建强,聂改红.替吉奥胶囊联合放疗治疗乳腺癌的临床疗效及对肿瘤标志物、人类表皮生长因子受体-2、中期因子水平的影响研究[J].中国临床药理学与治疗学,2017,22(8):899-903.
[8]王松,薛文华,赵晓玉,等.多西他赛、表柔比星联合环磷酰胺对不同分子分型乳腺癌患者临床疗效及肿瘤标志物表达的影响[J].中国药房,2017,28(23):3212-3216.
[9]黄烨,王飞,杨晓燕,等.血清肿瘤标志物联合检测在维吾尔族乳腺癌诊断中的应用价值[J].新疆医科大学学报,2017,40(4):437-441.
[10]王英,李佩章,黄玲莎,等.HE4和CA153联合表达在预测早期乳腺癌淋巴结转移中的意义[J].现代肿瘤医学,2017,25(3):390-392.
[11]姜贻乾,郭庆敏,谷建钟,等.微小RNA-29 b对乳腺癌细胞增殖和迁移的影响及其分子生物学机制[J].浙江大学学报:医学版,2017,46(4):349-356.
[12]张建祥,李建华,王芳,等.微小RNA-124靶向信号传导与转录激活因子3抑制乳腺癌增殖和侵袭的机制[J].中华实验外科杂志,2017,34(13):2105-2108.
[13]陈莉林,卢传辉,王淳阅,等.乳腺癌组织中mi RNA-214的表达及其与患者临床病理特征和预后的关系[J].中国妇幼保健,2017,32(24):6287-6289.
[14]吴钧,余丽莉,王晓明,等.血浆长链非编码RNA肺腺癌转移相关转录本1在乳腺癌中的表达及其临床意义[J].中华检验医学杂志,2018,41(2):92-96.
[15]袁超.血清miR-6861-5p检测在乳腺癌临床诊治中的价值探讨[J].中国肿瘤临床,2018,45(5):241-245.
[16]刘新唐,李玉柱,韩龙才,等.血清CA153、TPS、CYFRA21-1检测联合钼靶X摄影在乳腺癌早期诊断中的价值[J].中国热带医学,2018,18(2):150-153.
[17]张素强.乳腺癌患者手术前后外周血清CEA和CA15-3水平变化的价值研究[J].中国实用医刊,2017,44(16):114-117.
[18]黄远生,贾举闻,葛麟,等.Galectin-3和CA153及TS-GF检测对乳腺癌的诊断价值[J].中国现代普通外科进展,2017,20(10):833-835.
[19] Shimomura A,Shiino S,Kawauchi J,et al. Novel combi-nation of serum microRNA for detecting breast cancer inthe early stage[J]. Cancer Sci,2016,107(3):326-334.
[20]蒋安科,鄢传经.乳腺癌改良根治术患者血清CYFRA21-1、TK1及CA15-3水平变化及其与术后复发的相关性研究[J].转化医学杂志,2018,7(2):79-81.
[2]张同成,陆振一,薛世航,等.CA153、CA125、CA199、AFP和CEA在海岛地区农村乳腺癌中的诊断意义[J].现代实用医学,2017,29(11):1492-1494.
[3]戴建刚,吴永丰,李美,等.乳腺癌患者肿瘤标志物、免疫球蛋白、TNF-α和hs-CRP水平的变化及其临床意义[J].海南医学院学报,2017,23(20):2822-2825.
[4]梅虹,李常恩,杨梁,等.长链非编码RNA LINC01001在乳腺癌中的表达及其对MCF-7细胞增殖的影响[J].中国肿瘤生物治疗杂志,2018,25(2):158-162.
[5]杨文蔚,王志恒,岳朝艳,等.乳腺癌患者血清CA153、CEA、铁蛋白和降钙素水平的变化及临床意义[J].检验医学,2017,32(4):308-310.
[6]吴立春,谷仕艳,代黄梅,等.长链非编码RNA-ROR在乳腺癌患者血清、癌组织中的表达变化及其临床意义[J].山东医药,2017,57(32):78-80.
[7]闫建强,聂改红.替吉奥胶囊联合放疗治疗乳腺癌的临床疗效及对肿瘤标志物、人类表皮生长因子受体-2、中期因子水平的影响研究[J].中国临床药理学与治疗学,2017,22(8):899-903.
[8]王松,薛文华,赵晓玉,等.多西他赛、表柔比星联合环磷酰胺对不同分子分型乳腺癌患者临床疗效及肿瘤标志物表达的影响[J].中国药房,2017,28(23):3212-3216.
[9]黄烨,王飞,杨晓燕,等.血清肿瘤标志物联合检测在维吾尔族乳腺癌诊断中的应用价值[J].新疆医科大学学报,2017,40(4):437-441.
[10]王英,李佩章,黄玲莎,等.HE4和CA153联合表达在预测早期乳腺癌淋巴结转移中的意义[J].现代肿瘤医学,2017,25(3):390-392.
[11]姜贻乾,郭庆敏,谷建钟,等.微小RNA-29 b对乳腺癌细胞增殖和迁移的影响及其分子生物学机制[J].浙江大学学报:医学版,2017,46(4):349-356.
[12]张建祥,李建华,王芳,等.微小RNA-124靶向信号传导与转录激活因子3抑制乳腺癌增殖和侵袭的机制[J].中华实验外科杂志,2017,34(13):2105-2108.
[13]陈莉林,卢传辉,王淳阅,等.乳腺癌组织中mi RNA-214的表达及其与患者临床病理特征和预后的关系[J].中国妇幼保健,2017,32(24):6287-6289.
[14]吴钧,余丽莉,王晓明,等.血浆长链非编码RNA肺腺癌转移相关转录本1在乳腺癌中的表达及其临床意义[J].中华检验医学杂志,2018,41(2):92-96.
[15]袁超.血清miR-6861-5p检测在乳腺癌临床诊治中的价值探讨[J].中国肿瘤临床,2018,45(5):241-245.
[16]刘新唐,李玉柱,韩龙才,等.血清CA153、TPS、CYFRA21-1检测联合钼靶X摄影在乳腺癌早期诊断中的价值[J].中国热带医学,2018,18(2):150-153.
[17]张素强.乳腺癌患者手术前后外周血清CEA和CA15-3水平变化的价值研究[J].中国实用医刊,2017,44(16):114-117.
[18]黄远生,贾举闻,葛麟,等.Galectin-3和CA153及TS-GF检测对乳腺癌的诊断价值[J].中国现代普通外科进展,2017,20(10):833-835.
[19] Shimomura A,Shiino S,Kawauchi J,et al. Novel combi-nation of serum microRNA for detecting breast cancer inthe early stage[J]. Cancer Sci,2016,107(3):326-334.
[20]蒋安科,鄢传经.乳腺癌改良根治术患者血清CYFRA21-1、TK1及CA15-3水平变化及其与术后复发的相关性研究[J].转化医学杂志,2018,7(2):79-81.